KYMR
Kymera Therapeutics, Inc.
Set alert
126.63 USD +4.03 +3.29%
117.31 Day range 127.26
58.66 52-week range 127.31
- YTD
- +62.74%
- 1 year
- +106.10%
- Open
- 122.58
- Prev close
- 122.60
- Mkt cap
- 10.81B
- Vol
- 1.59M
- Avg vol
- 757.60K
- EPS
- -3.64
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 117.31
- High
- 127.26
- Forward P/E
- -24.89
- Beta
- 0.00
- Short ratio
- 10.32
- Inst. own
- 119.34%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 25, 2027
- 50-d avg
- 114.81
- 200-d avg
- 96.16
- 1y target
- 140.26
Financial health
Altman Z-Score
40.33 Safe zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
4 / 9 Average
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
C-1 / 5 overall
- DCF 1
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 4
- P/E 1
- P/B 1
Valuation
P/E -21.1×
FY 2018 5y median -13.5× FY 2025
P/S 168×
FY 2018 5y median 41.8× FY 2025
P/B 4.2×
FY 2018 5y median 3.8× FY 2025
P/FCF -28.0×
FY 2018 5y median -14.6× FY 2025
EV/EBITDA -20.8×
FY 2018 5y median -13.8× FY 2025
EV/Sales 161×
FY 2018 5y median 41.4× FY 2025
FCF Yield -3.6%
FY 2018 5y median -6.9% FY 2025
Profitability
Gross Margin 100.0%
FY 2018 5y median 100.0% FY 2025
Operating Margin -891.3%
FY 2018 5y median -344.4% FY 2025
Net Margin -794.4%
FY 2018 5y median -330.6% FY 2025
ROE -19.7%
FY 2018 5y median -26.8% FY 2025
ROIC -20.9%
FY 2018 5y median -28.3% FY 2025
ROA -17.9%
FY 2018 5y median -22.9% FY 2025
Growth (YoY)
Revenue -16.7%
FY 2018 FY 2025
Operating Income -33.5%
FY 2018 FY 2025
EPS (diluted) -23.8%
FY 2018 FY 2025
Free Cash Flow -13.0%
FY 2018 FY 2025
Financial Health
Current Ratio 10.5×
FY 2018 5y median 5.9× FY 2025
Quick Ratio 10.5×
FY 2018 5y median 5.9× FY 2025
Debt / Equity 0.1×
FY 2018 5y median 0.1× FY 2025
Net Debt / EBITDA 0.9×
FY 2018 5y median 0.3× FY 2025
Interest Coverage -1403×
FY 2018 5y median -916× FY 2025
Dividends
Dividend Yield 0.0%
FY 2018 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2018 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31